ELRIG 2025: AI, Robotics & Drug Discovery Insights

As a premier life science service provider and a conference partner, Pharmaron, who were situated at booth C20, was excited to demonstrate our commitment to drug discovery and connecting with the life science industry. The attending team also presented a range of exceptional science, including:

• Omar Loss’s presentation on ‘in vitro biology characterization of two novel inhibitors targeting the different domains of DNA polymerase theta (Polθ)’
• Three posters presented by:
  • Delia Brustur on ‘Enhancement of Pharmaron’s Fragment Platform’
  • Chris Wellaway on ‘Direct-to-Biology (D2B) Approach for Accelerated Targeted Protein Degrader Discovery‘’
  • Michael Bestwick ‘From Lick to Lead: Use of an in vivo Screening Model to find Novel Potent Bitter Taste Blockers’

Omar Loss presenting at ELRIG 2025.

ERLIG Drug Discovery has always been a key fixture in the life science calendar, as Sidonie Aubert, Business Development Manager at Pharmaron notes:

“ELRIG was a great success, providing a unique opportunity to connect with existing clients and engage potential new partners, particularly within the academic ecosystem. Beyond networking, the event provided insights into emerging trends and innovative research (use of AI in drug discovery, direct-to-biology, etc.), reinforcing its importance as a strategic platform for connecting with key stakeholders in our industry.”

Chris Wellaway presenting on Direct-to-Biology